JP2020517654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517654A5 JP2020517654A5 JP2019557358A JP2019557358A JP2020517654A5 JP 2020517654 A5 JP2020517654 A5 JP 2020517654A5 JP 2019557358 A JP2019557358 A JP 2019557358A JP 2019557358 A JP2019557358 A JP 2019557358A JP 2020517654 A5 JP2020517654 A5 JP 2020517654A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- lymphoma
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc1ccccc1-c(cc1)ccc1-c1cc(C(*)=O)c2[n](C)nnc2c1 Chemical compound Cc1ccccc1-c(cc1)ccc1-c1cc(C(*)=O)c2[n](C)nnc2c1 0.000 description 3
- XFLLIASBLKVRQQ-UHFFFAOYSA-N CC(c1c2[n](C)nnc2cc(-c(cc2)ccc2-c2ccccc2C)c1)=O Chemical compound CC(c1c2[n](C)nnc2cc(-c(cc2)ccc2-c2ccccc2C)c1)=O XFLLIASBLKVRQQ-UHFFFAOYSA-N 0.000 description 1
- RFKLWCDKUOPTKJ-UHFFFAOYSA-N CC1(C=CC(c2ccccc2)=CC1)c1cc(C(N=O)=O)c2[n](C)nnc2c1 Chemical compound CC1(C=CC(c2ccccc2)=CC1)c1cc(C(N=O)=O)c2[n](C)nnc2c1 RFKLWCDKUOPTKJ-UHFFFAOYSA-N 0.000 description 1
- SWSSMZKCNZKFFR-UHFFFAOYSA-N C[n]1nc2c(C(N)=O)cc(-c(cc3)ccc3-c3ccccc3)cc2c1 Chemical compound C[n]1nc2c(C(N)=O)cc(-c(cc3)ccc3-c3ccccc3)cc2c1 SWSSMZKCNZKFFR-UHFFFAOYSA-N 0.000 description 1
- AGPUYFMACXDOSL-UHFFFAOYSA-N C[n]1nc2c(C(O)=O)cc(-c(c(F)c(c(-c3ccccc3)c3F)F)c3F)cc2n1 Chemical compound C[n]1nc2c(C(O)=O)cc(-c(c(F)c(c(-c3ccccc3)c3F)F)c3F)cc2n1 AGPUYFMACXDOSL-UHFFFAOYSA-N 0.000 description 1
- OFVDCPSBIDEOHI-UHFFFAOYSA-N C[n]1nc2c(C(O)=O)cc(-c(cc3)ccc3-c3cc(CN4CCCCC4)ccc3)cc2n1 Chemical compound C[n]1nc2c(C(O)=O)cc(-c(cc3)ccc3-c3cc(CN4CCCCC4)ccc3)cc2n1 OFVDCPSBIDEOHI-UHFFFAOYSA-N 0.000 description 1
- GBPUGCIDDBWGOK-UHFFFAOYSA-N C[n]1nnc2cc(-c(c(F)c(c(-c3ccccc3)c3F)F)c3F)cc(C(O)=O)c12 Chemical compound C[n]1nnc2cc(-c(c(F)c(c(-c3ccccc3)c3F)F)c3F)cc(C(O)=O)c12 GBPUGCIDDBWGOK-UHFFFAOYSA-N 0.000 description 1
- NDUXPIXMXWOFOK-UHFFFAOYSA-N Cc(cccc1)c1-c(cc1)ccc1-c1cc(N=NC2)c2c(C(N)=O)c1 Chemical compound Cc(cccc1)c1-c(cc1)ccc1-c1cc(N=NC2)c2c(C(N)=O)c1 NDUXPIXMXWOFOK-UHFFFAOYSA-N 0.000 description 1
- ULWBTFJGCCNURF-UHFFFAOYSA-N Cc1ccc(C)[n]1-c(cc1)ccc1-c1cc(C(O)=O)c2[n](C)nnc2c1 Chemical compound Cc1ccc(C)[n]1-c(cc1)ccc1-c1cc(C(O)=O)c2[n](C)nnc2c1 ULWBTFJGCCNURF-UHFFFAOYSA-N 0.000 description 1
- LHSBCMLEEPGSCA-UHFFFAOYSA-N Cc1ccccc1-c(cc1)ccc1-c1cc(C(O)=O)c2[I](C)N=Nc2c1 Chemical compound Cc1ccccc1-c(cc1)ccc1-c1cc(C(O)=O)c2[I](C)N=Nc2c1 LHSBCMLEEPGSCA-UHFFFAOYSA-N 0.000 description 1
- RYZQWKBCHRLRJP-UHFFFAOYSA-N Cc1ccccc1-c(cc1)ccc1-c1cc2n[n](C)nc2c(C(O)=O)c1 Chemical compound Cc1ccccc1-c(cc1)ccc1-c1cc2n[n](C)nc2c(C(O)=O)c1 RYZQWKBCHRLRJP-UHFFFAOYSA-N 0.000 description 1
- RFLWCJMCXNNHJX-UHFFFAOYSA-N Cc1ccccc1-c(cc1)ccc1C(C=C1N=NN(C)C11)=CC1C(O)=O Chemical compound Cc1ccccc1-c(cc1)ccc1C(C=C1N=NN(C)C11)=CC1C(O)=O RFLWCJMCXNNHJX-UHFFFAOYSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022193406A JP2023022252A (ja) | 2017-04-24 | 2022-12-02 | ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法 |
| JP2025128059A JP2025156453A (ja) | 2017-04-24 | 2025-07-31 | ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/494,820 US9937155B2 (en) | 2013-02-25 | 2017-04-24 | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| US15/494,820 | 2017-04-24 | ||
| US15/899,707 | 2018-02-20 | ||
| US15/899,707 US20180369206A1 (en) | 2017-04-24 | 2018-02-20 | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| PCT/IB2018/052710 WO2018197997A1 (en) | 2017-04-24 | 2018-04-19 | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193406A Division JP2023022252A (ja) | 2017-04-24 | 2022-12-02 | ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517654A JP2020517654A (ja) | 2020-06-18 |
| JP2020517654A5 true JP2020517654A5 (https=) | 2021-05-27 |
| JP7225114B2 JP7225114B2 (ja) | 2023-02-20 |
Family
ID=65803213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019557358A Active JP7225114B2 (ja) | 2017-04-24 | 2018-04-19 | ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法 |
| JP2022193406A Pending JP2023022252A (ja) | 2017-04-24 | 2022-12-02 | ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法 |
| JP2025128059A Pending JP2025156453A (ja) | 2017-04-24 | 2025-07-31 | ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193406A Pending JP2023022252A (ja) | 2017-04-24 | 2022-12-02 | ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法 |
| JP2025128059A Pending JP2025156453A (ja) | 2017-04-24 | 2025-07-31 | ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12290507B2 (https=) |
| EP (2) | EP3915557A1 (https=) |
| JP (3) | JP7225114B2 (https=) |
| KR (2) | KR102678263B1 (https=) |
| CN (1) | CN110662539B (https=) |
| AU (2) | AU2018260390B2 (https=) |
| CA (1) | CA3060390A1 (https=) |
| CY (1) | CY1124702T1 (https=) |
| DK (1) | DK3615027T3 (https=) |
| EA (1) | EA201992528A1 (https=) |
| ES (1) | ES2889100T3 (https=) |
| HR (1) | HRP20211462T1 (https=) |
| HU (1) | HUE056485T2 (https=) |
| IL (1) | IL270066B2 (https=) |
| LT (1) | LT3615027T (https=) |
| MA (1) | MA48459B1 (https=) |
| MD (1) | MD3615027T2 (https=) |
| MX (1) | MX2019012640A (https=) |
| PH (1) | PH12019502402A1 (https=) |
| PL (1) | PL3615027T3 (https=) |
| PT (1) | PT3615027T (https=) |
| RS (1) | RS62519B1 (https=) |
| SG (1) | SG11201909718QA (https=) |
| SI (1) | SI3615027T1 (https=) |
| SM (1) | SMT202100553T1 (https=) |
| TW (1) | TWI821180B (https=) |
| UA (1) | UA129244C2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA48459B1 (fr) | 2017-04-24 | 2021-09-30 | Aurigene Discovery Tech Ltd | Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase |
| KR102861339B1 (ko) * | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| KR20230078997A (ko) * | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
| KR102514860B1 (ko) * | 2020-12-01 | 2023-03-29 | 한국과학기술연구원 | 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010701D1 (de) | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO1996035419A1 (en) | 1995-05-10 | 1996-11-14 | Pfizer Inc. | Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis |
| US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| JP2003510352A (ja) | 1999-10-01 | 2003-03-18 | インスティチュート オブ モレキュラー アンド セル バイオロジー | ウイルス媒介性疾病の治療用化合物 |
| MXPA04000224A (es) * | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
| PL382308A1 (pl) | 2004-08-25 | 2007-08-20 | Targegen, Inc. | Związki heterocykliczne i sposoby stosowania |
| ATE474833T1 (de) | 2004-09-22 | 2010-08-15 | Janssen Pharmaceutica Nv | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| JP2007015952A (ja) | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| DE102005049953A1 (de) * | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| EP2066319B1 (en) | 2006-09-08 | 2012-02-01 | F. Hoffmann-La Roche AG | Benzotriazole kinase modulators |
| EP2387568A1 (en) | 2009-01-19 | 2011-11-23 | NeuroSearch A/S | Novel benzotriazole derivatives useful for the treatment of cns disorders |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| US9316632B2 (en) | 2009-03-17 | 2016-04-19 | Marshall University Research Corporation | Methods of screening chemotherapeutic agents and treating cancer |
| WO2010115736A2 (en) | 2009-04-02 | 2010-10-14 | Merck Serono S.A. | Dihydroorotate dehydrogenase inhibitors |
| JP5967827B2 (ja) * | 2009-12-09 | 2016-08-10 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物 |
| US20130109643A1 (en) * | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| CN103476770B (zh) | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| WO2013049112A1 (en) | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
| CN103965133B (zh) | 2013-01-31 | 2018-11-30 | 华东理工大学 | 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途 |
| HRP20181908T1 (hr) * | 2013-02-25 | 2019-01-11 | Aurigene Discovery Technologies Limited | Derivati trosupstituiranog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PL3139914T3 (pl) | 2014-05-08 | 2023-11-27 | Kiora Pharmaceuticals Gmbh | Związki stosowane w leczeniu chorób i schorzeń okulistycznych |
| WO2017037022A1 (en) | 2015-09-01 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Compounds and methods useful for treating or preventing hematological cancers |
| EP3397625A4 (en) | 2015-12-30 | 2019-12-25 | Agios Pharmaceuticals, Inc. | TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| US11311548B2 (en) | 2017-03-02 | 2022-04-26 | Aslan Pharmaceuticals Pte. Ltd. | Cancer therapy |
| MA48459B1 (fr) | 2017-04-24 | 2021-09-30 | Aurigene Discovery Tech Ltd | Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| WO2019012030A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| JP7126556B2 (ja) | 2018-09-28 | 2022-08-26 | 富士フイルム株式会社 | シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤 |
| JP7608336B2 (ja) | 2018-11-30 | 2025-01-06 | フォンダッツィオーネ・セントロ・サン・ラッファエーレ | 中枢神経系原発リンパ腫の併用治療 |
| PE20212197A1 (es) | 2018-12-21 | 2021-11-16 | Les Laboratoires Servier Sas | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo |
| WO2021062157A1 (en) | 2019-09-27 | 2021-04-01 | The Rockefeller University | Compositions and methods for treating metastatic gastrointestinal cancer |
| WO2021262874A1 (en) | 2020-06-24 | 2021-12-30 | Servier Pharmaceuticals , Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| CA3184024A1 (en) | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| KR20230078997A (ko) | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
-
2018
- 2018-04-19 MA MA48459A patent/MA48459B1/fr unknown
- 2018-04-19 SI SI201830423T patent/SI3615027T1/sl unknown
- 2018-04-19 SM SM20210553T patent/SMT202100553T1/it unknown
- 2018-04-19 EP EP21184786.8A patent/EP3915557A1/en active Pending
- 2018-04-19 RS RS20211150A patent/RS62519B1/sr unknown
- 2018-04-19 JP JP2019557358A patent/JP7225114B2/ja active Active
- 2018-04-19 EA EA201992528A patent/EA201992528A1/ru unknown
- 2018-04-19 SG SG11201909718Q patent/SG11201909718QA/en unknown
- 2018-04-19 KR KR1020197034384A patent/KR102678263B1/ko active Active
- 2018-04-19 IL IL270066A patent/IL270066B2/en unknown
- 2018-04-19 HU HUE18723602A patent/HUE056485T2/hu unknown
- 2018-04-19 AU AU2018260390A patent/AU2018260390B2/en active Active
- 2018-04-19 PL PL18723602T patent/PL3615027T3/pl unknown
- 2018-04-19 MX MX2019012640A patent/MX2019012640A/es unknown
- 2018-04-19 PT PT187236021T patent/PT3615027T/pt unknown
- 2018-04-19 DK DK18723602.1T patent/DK3615027T3/da active
- 2018-04-19 CA CA3060390A patent/CA3060390A1/en active Pending
- 2018-04-19 HR HRP20211462TT patent/HRP20211462T1/hr unknown
- 2018-04-19 EP EP18723602.1A patent/EP3615027B1/en active Active
- 2018-04-19 MD MDE20200226T patent/MD3615027T2/ro unknown
- 2018-04-19 CN CN201880027155.0A patent/CN110662539B/zh active Active
- 2018-04-19 KR KR1020247020497A patent/KR102756047B1/ko active Active
- 2018-04-19 UA UAA201911329A patent/UA129244C2/uk unknown
- 2018-04-19 ES ES18723602T patent/ES2889100T3/es active Active
- 2018-04-19 LT LTEPPCT/IB2018/052710T patent/LT3615027T/lt unknown
- 2018-04-23 TW TW107113690A patent/TWI821180B/zh active
-
2019
- 2019-10-23 PH PH12019502402A patent/PH12019502402A1/en unknown
-
2021
- 2021-10-04 CY CY20211100855T patent/CY1124702T1/el unknown
- 2021-10-14 US US17/501,701 patent/US12290507B2/en active Active
-
2022
- 2022-12-02 JP JP2022193406A patent/JP2023022252A/ja active Pending
-
2024
- 2024-07-25 AU AU2024205090A patent/AU2024205090A1/en active Pending
-
2025
- 2025-04-30 US US19/195,209 patent/US20260097019A1/en active Pending
- 2025-07-31 JP JP2025128059A patent/JP2025156453A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020075934A5 (https=) | ||
| JP2020517654A5 (https=) | ||
| KR102783756B1 (ko) | 선택적 에스트로겐 수용체 분해제 | |
| TWI429635B (zh) | 蛋白質激酶抑制劑 | |
| CN108024993B (zh) | 取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂 | |
| US11976064B2 (en) | Toll-like receptor agonists | |
| RU2017139515A (ru) | Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там | |
| JP2020506951A5 (https=) | ||
| WO2018226150A1 (en) | Pyrazolopyrimidine as malt-1 inhibitors | |
| DK3027602T3 (en) | NEW INDO AND PYROL RELEASE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| EA011888B1 (ru) | Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом | |
| JP2016504365A (ja) | Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用 | |
| RU2007110480A (ru) | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы | |
| JP2020536971A5 (https=) | ||
| JP2021524835A (ja) | Ａｘｌキナーゼ阻害剤およびその使用 | |
| CN106883193A (zh) | 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用 | |
| JP2020503376A5 (https=) | ||
| US10646464B2 (en) | Methods for treating cancer | |
| EP3372231B1 (en) | Pharmaceutical composition for cancer immunotherapy purposes and/or immunostimulation purposes which contains diamino heterocyclic carboxamide compound as active ingredient | |
| CN107683137A (zh) | 用于使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法 | |
| CN107708700A (zh) | 用于治疗癌症的方法 | |
| JP2014005265A5 (https=) | ||
| CN113597309A (zh) | 抗肿瘤组合物 | |
| CN118488945A (zh) | 磺酰胺核糖核苷酸还原酶(rnr)抑制剂及其用途 | |
| KR20240099239A (ko) | 결장직장암에 대한 전임상 활성을 갖는 종양원성 chd1l의 소분자 |